Meeting
2024 ASCO Genitourinary Cancers Symposium
Understanding variation in treatment intensification for de novo metastatic castration-sensitive prostate cancer (mCSPC): A population-based cohort study.
Authors
Christopher J.D. Wallis
Division of Urology, University of Toronto, Toronto, ON, Canada
Christopher J.D. Wallis , Raj Satkunasivam , David-Dan Nguyen , Khatereh J.D. Aminoltejari , Amanda Elizabeth Hird , Soumyajit Roy , Scott C. Morgan , Shawn Malone , Bobby Shayegan , Rodney H. Breau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 69)
DOI
10.1200/JCO.2024.42.4_suppl.69
Abstract #
69
Poster Bd #
C4
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Survival Outcomes of APA as a Starting treatment: Impact in real-world patients with mCSPC (OASIS)
First Author: Benjamin L. Maughan
Poster
2022 ASCO Genitourinary Cancers Symposium
Evolving real-world patterns of practice in metastatic castration-sensitive prostate cancer (mCSPC): The genitourinary research consortium (GURC) national multicenter cohort study.
First Author: Steven Yip
Poster
2024 ASCO Genitourinary Cancers Symposium
Clinical and patient factors associated with treatment intensification for metastatic castration-sensitive prostate cancer.
First Author: Sreevalsa Appukkuttan
Poster
2024 ASCO Genitourinary Cancers Symposium
Interaction of age and benefit of treatment intensification in advanced prostate cancer: An aggregate meta-analysis of 14 randomized trials.
First Author: Alicia K. Morgans